MD Anderson reported first‑in‑human data for RB‑1355, an engineered immune cell therapy tested in relapsed or refractory non‑Hodgkin lymphoma. The initial study showed acceptable safety and signals of efficacy, including responses in patients who had exhausted standard options, according to the center’s release. Investigators highlighted the therapy’s ability to elicit tumor control in a heavily pretreated cohort and outlined next steps for dose escalation and combination strategies. The readout positions RB‑1355 as a candidate for broader clinical development if durability and safety are confirmed.